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Inflammation plays a significant role in the pathophysiology
of renal ischemia-reperfusion injury. Local inflammation is
modulated by the brain via the vagus nerve and nicotinic
acetylcholine receptors such that electrical or pharmacologic
stimulation of this cholinergic anti-inflammatory pathway
results in suppression of proinflammatory cytokine
production. We examined the effects of cholinergic
stimulation using agonists, nicotine or GTS-21, given before
or after bilateral renal ischemia-reperfusion injury in rats.
Pretreatment of rats with either agonist significantly
attenuated renal dysfunction and tubular necrosis induced
by renal ischemia. Similarly, tumor necrosis factor-a protein
expression and leukocyte infiltration of the kidney were
markedly reduced following treatment with cholinergic
agonists. We found functional nicotinic acetylcholine
receptors were present on rat proximal tubule epithelial cells.
Cholinergic stimulation significantly decreased tubular
necrosis in vagotomized rats after injury, implying an intact
vagus nerve is not required for this renoprotective effect.
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Renal ischemia–reperfusion (I/R) injury, the leading cause of
acute renal injury, is commonly encountered in clinical
situations such as trauma, aortic bypass surgery, hemorrhagic
shock, and renal transplantation.1 I/R injury has a high
morbidity and mortality in patients with native kidneys and
contributes significantly to delayed graft function and acute
rejection in the short-term and chronic rejection later after
transplantation. Unfortunately, effective prophylactic/thera-
peutic modalities are non-existent.1–4
The mechanisms underlying I/R injury are complex and
incompletely understood.5–6 Cytokine (for example, tumor
necrosis factor, TNF) release from the damaged organ or
tissue occurs early.7–8 TNF then acts as a proximal mediator
to stimulate the expression of other cytokines and chemo-
kines. TNF also activates the endothelium to express adhesion
molecules and additional proinflammatory molecules.
Collectively, these agents then trigger the infiltration of
proinflammatory cells into the tubulointerstitium to promote
further inflammation, which adds to the tissue damage.8–13
Renal tubular epithelial cells play an important role in the
inflammatory response by producing cytokines.14 Strategies
that inhibit macrophage and endothelial cell activation
therefore may help prevent and treat I/R injury.15–17
The cholinergic anti-inflammatory pathway (CAP) is a
novel physiological mechanism through which the brain
modulates inflammation at various locations in the body
through the vagus nerve and nicotinic acetylcholine receptors
(nAChRs) expressed by peripheral cells.18–21 Experimental
activation of the CAP by direct electrical stimulation of
efferent vagus nerve inhibits the synthesis of TNF in the liver,
spleen, and heart and attenuates serum TNF levels during
endotoxemia, hemorrhagic shock, and other diseases asso-
ciated with excessive cytokine release.18–23 In addition, choli-
nergic stimulation blocks endothelial cell activation and
leukocyte recruitment during inflammation.24 Acetylcholine
released by stimulation of the vagus nerve binds to nAChRs
expressed by macrophages and other immunocompetent cells
that modulate or participate in the inflammatory response
to suppress proinflammatory cytokine production.19,20 The
nAChRs are comprised of five receptor subunits, including
a1–10, b1–4, g, d, and e, which form ligand-gated ion
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channels.25 The subunits fall into two broad groups: neuronal
nicotinic receptors (consisting of a2–10 and b2–4) and
muscle nicotinic receptors (consisting of a1, b1, g, d, and e
subunits). The neuronal receptors are further subclassified
into either homomeric nAChRs (for example, a7 or a9)
or heteromeric nAChRs (consisting of combinations of a and
b subunits, for example, a3b2). These neuronal nAChRs
were first described in the nervous system where they mediate
many physiological functions.26 Many nAChRs have been
demonstrated in non-neuronal tissues/cells, including
placental epithelial cells,27 the urothelium,28 and endothelial
cells.29 Cholinergic agonists (including nicotine and GTS-21)
produce effects similar to the electrical stimulation of the
vagus nerve.30–34 In this study, we investigated the effects of
pharmacologic cholinergic stimulation in both normal and
vagotomized rats after a standardized renal I/R injury.16,35,36
RESULTS
Cholinergic agonists reduce renal dysfunction following
I/R injury
Renal function was assessed by plasma creatinine levels.
As expected, vehicle (saline)-treated rats subjected to 45 min
of ischemia followed by 24 h of reperfusion experienced
a significant increase in plasma creatinine levels compared
to the sham-operated animals. Preischemic treatment with
either nicotine or GTS-21 (a selective a7nAChR agonist)
markedly reduced plasma creatinine levels 24 h after reper-
fusion compared to the saline-treated group (Figure 1a).
Treatment with nicotine showed a dose-dependent improve-
ment in I/R-induced renal dysfunction (Figure 1b). Delayed
treatment with nicotine or GTS-21 (first dose given 2 h post-
reperfusion) did not significantly improve renal function
compared to saline-treated rats (data not shown).
Cholinergic agonists ameliorate acute tubular damage
following renal I/R injury
Although no morphological changes were observed in the
kidneys of sham-operated rats (Figure 2a), severe and
extensive acute tubular damage was observed in the cortex
and outer medulla in saline-treated rats 24 h after reperfu-
sion. This was manifested as tubular epithelial cell necrosis,
tubular dilatation, and proteinaceous cast formation in the
cortex and outer medullary zones (Figure 2b). Pretreatment
with nicotine or GTS-21 reduced the extent and severity of
injury (Figure 2c and d). Semiquantitative scoring of the
acute tubular necrosis was performed by an experienced renal
pathologist (blinded to the experimental groups). Preis-
chemic treatment with either nicotine or GTS-21 significantly
attenuated the acute tubular necrosis scores compared to the
saline-treated group (Figure 3a). Treatment with nicotine
showed a dose-dependent improvement in renal tubular
damage (Figure 3b). Delayed treatment with the cholinergic
agonists did not significantly protect the kidneys from acute
tubular necrosis (data not shown). A strong correlation
between plasma creatinine levels and tubular necrosis scores
(the two main measures of renal injury in this model) was
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Figure 1 | Cholinergic agonists reduce plasma creatinine levels
following renal I/R injury. (a) Rats underwent I/R surgery
following pretreatment with either saline (vehicle), nicotine (Nic,
1 mg kg1), or GTS-21 (10 mg kg1). (b) The effect of increasing
doses of nicotine on renal function after I/R injury is shown. The
lowest dose used (0.2 mg kg1) did not produce a significant
improvement. Values are expressed as mean±s.e.m. (n¼ 5–6 rats
per group). *Po0.001; **Po0.0001.
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Figure 2 | Cholinergic stimulation reduces renal damage
following renal I/R injury. Kidneys were processed and stained
with hematoxylin and eosin. Representative photomicrograghs
are shown. (a) Essentially normal histology (sham-operated rats).
(b) Saline-treated rats following I/R injury with severe tubular
damage, including vascular congestion, tubular dilatation (TD),
proteinaceous casts (PC), and tubular necrosis (TN). Preischemic
treatment with (c) nicotine (1 mg kg1) or (d) GTS-21 (10 mg kg1)
reduced the extent of tubular damage. Original magnification
 200.
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observed (Pearson correlation coefficient¼ 0.73), suggesting
that the plasma creatinine can be used as a substitute for the
tubular necrosis score.
Cholinergic agonists inhibit neutrophil infiltration following
renal I/R injury
Neutrophils mediate/promote the acute inflammatory
response after I/R injury. Infiltration of neutrophils following
I/R injury was assessed using Leder-stained kidney sections.
I/R injury significantly increased the number of kidney-
infiltrating neutrophils in saline-treated animals compared to
sham-operated animals. Pretreatment with either nicotine or
GTS-21 significantly blocked neutrophil accumulation within
the kidney following I/R compared to the saline-treated
animals (Figure 4a).
Cholinergic agonists suppress myeloperoxidase activity
following renal I/R injury
Accumulation of leukocytes in renal tissue at 24 h after
reperfusion was assessed by the determination of renal
myeloperoxidase (MPO) activity. MPO activity reflects both
macrophage and neutrophil infiltration.8 Renal tissue MPO
levels were elevated after I/R injury in saline-treated rats
compared to sham-operated rats. Pretreatment of rats with
either nicotine or GTS-21 significantly reduced renal MPO
activity compared to saline treatment (Figure 4b).
Cholinergic agonists inhibit renal TNF production following
I/R injury
To explore the mechanism by which the cholinergic agonists
attenuate renal I/R injury in this model, we measured kidney
TNF levels. TNF is a proximal mediator of inflammation
following I/R injury and it promotes tissue injury at the site
of inflammation. TNF was markedly elevated 24 h after
reperfusion in the saline-treated group compared to sham-
operated rats. Preischemic treatment with either nicotine or
GTS-21 significantly reduced kidney TNF levels compared to
saline treatment (Figure 5).
Nicotine attenuates renal injury in vagotomized animals
following I/R injury
Next, we examined the effect of cholinergic stimulation in
kidneys lacking vagal innervation, which occurs in clinical renal
transplants; previously vagotomized animals underwent renal
I/R injury with or without previous treatment with nicotine.
Pretreatment of vagotomized animals with nicotine significantly
attenuated renal damage after I/R injury, as determined by the
tubular necrosis scores, compared to saline treatment (Figure 6).
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Figure 3 | Cholinergic agonists improve tubular necrosis
scores following renal I/R injury. (a) Pretreatment with nicotine
(Nic, 1 mg kg1) or GTS-21 (10 mg kg1) significantly attenuated
the extent of renal injury. (b) The effect of increasing doses of
nicotine on tubular necrosis scores after I/R injury is shown. Values
are expressed as mean±s.e.m. (n¼ 5–7 rats per group). *Po0.05;
**Po0.001.
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Figure 4 | Cholinergic agonists inhibit renal leukocyte
infiltration following I/R injury. The neutrophil count was
obtained from Leder-stained kidney sections, and the combined
neutrophil and macrophage infiltration into the kidney was
assessed by the MPO activity. Pretreatment with either nicotine
(Nic, 1 mg kg1) or GTS-21 (10 mg kg1) significantly reduced the
renal (a) neutrophil count and (b) MPO activity. Values are
expressed as mean±s.e.m. (n¼ 5–7 rats per group). *Po0.05;
**Po0.001; ***Po0.0001.
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Tubular epithelial cells constitutively express nAChR subunit
mRNA and protein
We investigated the expression of nAChR subunit mRNA in
rat tubular epithelial cells. We observed a1–7, a9, a10, and
b1–4 subunit mRNA expression (Figure 7a). The primers for
each subunit yielded products of expected size. On the basis
of the nAChR subunit mRNA expression, we determined that
most of the possible nAChRs in the cells would contain one
or more of the a2, a3, or a7 subunits. By using antibodies to
these three subunits, flow cytometry showed that the tubular
epithelial cells constitutively express a2, a3, and a7 subunit
proteins (Figure 7b).
Tubular cell nAChRs form functional receptors that are
inhibited by cholinergic antagonists
To assess whether nAChR subunits expressed by tubular
epithelial cells form functional receptors, we examined the
ability of nicotine to induce intracellular calcium ion flux.
Stimulation with nicotine (106 M) increased intracellular
calcium concentrations (Figure 7c). Calcium flux mediated
by nicotine was prevented by preincubation with the nAChR
antagonist, hexamethonium (103 M).
DISCUSSION
In this report, we demonstrate that cholinergic stimulation
using nicotine or GTS-21 (a selective a7nAChR agonist)
attenuates I/R-induced acute renal injury in a well-estab-
lished rat model. Rats that underwent renal ischemia
followed by reperfusion showed characteristic signs of renal
dysfunction and inflammation. These signs that include
elevated plasma creatinine, histologic changes consistent with
severe renal damage, and cellular infiltration are all typical of
severe I/R injury. Pretreatment with the cholinergic agonists
significantly reduced the tubular injury and renal dysfunc-
tion. The renoprotective effect was also seen in vagotomized
animals. In addition, we found a marked reduction in renal
TNF levels in animals that were pretreated with the
cholinergic agonists. Furthermore, for the first time we show
that tubular epithelial cells, the most vulnerable cells during
renal I/R injury, constitutively express functional nAChRs.
Together, our data identify a novel role for the CAP in renal
I/R injury and suggest a local effect of cholinergic stimulation.
The pivotal role of inflammation as a key mechanism in
renal I/R injury is well accepted.15–17,37,38 The recently
discovered CAP is a mechanism through which the central
nervous system regulates excessive inflammation and limits
self-damage. This pathway acts via the vagus nerve, which
innervates the viscera including the kidneys.39 The intracel-
lular mechanisms by which cholinergic stimulation blunts
cytokine production are not completely understood but
current knowledge suggests that the CAP acts at both the
transcriptional and post-transcriptional levels.
In this study, we used nicotine and GTS-21 to elucidate
the role of the CAP in renal I/R injury. GTS-21 is a selective
a7nAChR agonist; therefore, the effectiveness of GTS-21
suggests a specific role of the a7nAChR in mediating the
renoprotective effects. Although both significantly improved
the outcome as noted above, nicotine tended to have a
superior effect (Figures 1a and 3a). One reason may be
because GTS-21 is a partial agonist. Also, nicotine may act via
other nAChRs to augment its anti-inflammatory effects.
Matsunaga et al.40 demonstrated that nicotine may act
through a non-a7nAChR mechanism(s). Another explana-
tion for the apparent superior effects of nicotine may be due
to its effect on other cellular mechanisms, for instance
through the increased availability of nitric oxide (NO) in the
endothelium. NO release is impaired during I/R injury.41 The
reduced NO availability leads to vasoconstriction, which
worsens the outcome. Preliminary experiments from our
laboratory show that nicotine may increase NO in endothe-
lial cells. It is therefore possible that nicotine improves the
outcome in renal I/R injury through increased early NO
production.41–43
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Figure 6 | Nicotine attenuates renal injury in vagotomized
animals following I/R injury. Previously vagotomized rats
underwent I/R surgery following pretreatment with either saline
(vehicle) or nicotine (Nic, 1.5 mg kg1). Pretreatment with nicotine
significantly reduced the tubular necrosis scores. The nicotine
dose was chosen based on previous dose–response experiments.
Values are expressed as mean±s.e.m. (n¼ 6 rats per group).
**Po0.0001.
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Figure 5 | Cholinergic agonists suppress renal TNF protein
production following I/R injury. Renal I/R injury significantly
elevated TNF protein levels. Pretreatment with either nicotine
(Nic, 1 mg kg1) or GTS-21 (10 mg kg1) significantly reduced TNF
levels. Values are expressed as mean±s.e.m. (n¼ 4–7 rats per
group). *Po0.05; **Po0.0001.
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Our results are consistent with what is known about
cholinergic stimulation, including suppression of TNF,
reduced inflammation and leukocyte infiltration, and atte-
nuated organ dysfunction. The observed renoprotective
effects of nicotine in vagotomized animals suggest that
cholinergic agonists act on the cholinergic receptors locally
within the kidney and that an intact vagus nerve is not
required for the renoprotection. This finding is consistent
with what van Westerloo et al.31 found in experimental
peritonitis, where nicotine was still effective in controlling
peritonitis in vagotomized mice. After submitting our paper
for publication, Sadis et al.44 published a similar study
showing the renoprotective effects of nicotine during I/R
injury in mice. Using a7nAChR-knockout mice, they
demonstrated a role for the a7nAChR in mediating nicotine’s
protective effects.44 Their study, however, did not rule out the
potential role of other nAChRs, and they did not explore
local expression of nAChRs within the kidney. In addition,
that study did not examine the effect of nicotine in
vagotomized animals, which is important when considering
the clinical utility of such a treatment in renal transplant
recipients. Our data clearly suggest a role for cholinergic
agonists both in native and transplanted kidneys.
Delayed treatment with agonists 2 h after the onset of
reperfusion did not significantly protect the kidneys. This is
probably due to the fact that some preformed TNF-a is
released earlier during the ischemic phase and although
the (pre)transcriptional component of TNF-a release may
be attenuated, this may be too late to salvage the kidney.
This result has potential clinical implications especially
for transplanted kidneys concerning the timing of treatment
to achieve optimal results. For example, patients could be
pretreated with cholinergic agonists just before transplan-
tation. The same approach could be used to prevent
I/R-induced renal failure during abdominal vascular sur-
geries. Following intravenous administration to adult rats
(5 mg kg1), the elimination half-life of GTS-21 is approxi-
mately 3.7 h, indicating the need for multiple doses per day.45
The role of the CAP in various inflammatory conditions
continues to be explored. It is hoped that as we continue to
learn more about it and its signaling mechanisms, we will be
able to develop potent and selective agonists that lack the
many known side effects of nicotine.
In summary, our study demonstrates for the first time
that pretreatment with cholinergic agonists attenuates
acute tubular injury and renal dysfunction following renal
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I/R injury in rats. This protective effect is seen even in
vagotomized animals and appears to involve the a7nAChR
and an anti-inflammatory pathway centered on suppression
of TNF. The presence of functional nAChRs in rat tubular
epithelial cells (which are actively involved in I/R-mediated
inflammatory response) suggests a local effect of the
cholinergic agonists. CAP can be harnessed for the treatment
and prevention of I/R injury and other inflammatory
conditions.
MATERIALS AND METHODS
Reagents
GTS-21, a selective a7nAChR agonist also known as 3-(2,4-
dimethoxybenzylidene) anabaseine dihydrochloride, was provided
by Dr Yousef Al-Abed (The Feinstein Institute for Medical Research,
Manhasset, NY, USA). GTS-21 has been used in several in vivo
models at doses similar to that used in this study.46 Nicotine
(1-methyl-2-[3-pyridyl] pyrrolidine) and hexamethonium were
purchased from Sigma-Aldrich (St Louis, MO, USA). A transient,
mild limb twitching was observed with all the doses of nicotine
(0.2–1.5 mg kg1), otherwise no severe clinical side effects were
noted. All other reagents were commercial products of the highest
quality.
Cell culture
The well-characterized normal rat proximal tubular epithelial cell
line, NRK52E, was obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (with 4.5 g l1 glucose; Invitrogen, Grand
Island, NY, USA) containing 5% fetal bovine serum, 100 IU ml1
penicillin–streptomycin, and 2 mmol l1 glutamine in 5% CO2
at 37 1C.
Animals
Male Sprague–Dawley rats (250–350 g) purchased from Taconic
Farms (Germantown, NY, USA) were housed in light-controlled
room with a 12-h light–dark cycle and allowed free access to water
and standard rat chow. Rats were acclimatized for 1 week before
experimentation. All animals received humane care in compliance
with the National Research Council’s Guide for the Care and Use of
Laboratory Animals. The animal protocol was approved by the
Institutional Animal Care and Use Committee of the North Shore—
LIJ Health System.
Experimental groups
The following experimental groups were studied. Group 1 (n¼ 5)
received an intraperitoneal injection of nicotine (1 mg kg1 in
saline) 20 min before the renal vessel clamp. Group 2 (n¼ 5)
received an intraperitoneal injection of GTS-21 (10 mg kg1 in
saline) 20 min before renal vessel clamp. Group 3 (n¼ 7) received an
intraperitoneal injection of saline (vehicle) 20 min before the renal
vessel clamp. Groups 4 and 5 (n¼ 5 each) received the first injection
of either nicotine or GTS-21 2 h after reperfusion. Group 6 (n¼ 5)
underwent sham surgery without clamping of the renal vessels. In all
the groups, the treatment drug was repeated 6–8 h after the initial
dose. Subsequently, the effects of two lower doses of nicotine (0.2
and 0.4 mg kg1, n¼ 5 in each case) were studied. In a separate set
of experiments, 12 previously vagotomized animals received either
1.5 mg kg1 nicotine (n¼ 6) or saline (n¼ 6) 20 min before the
induction of I/R injury.
Flow cytometry
Confluent NRK52E cells were harvested using an enzyme-free
dissociation buffer. Flow cytometry analysis was performed using
polyclonal antibody against the a2, a3, and a7 nAChR subunits
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or an irrelevant
Ig isotype control. Staining was visualized with anti-goat Ig-PE (for
a2 and a7 subunits; Rockland Immunochemicals, Gilbertsville, PA,
USA) or anti-rabbit Ig-FITC (for a3 subunit; Jackson Laboratory,
Bar Harbor, Maine, USA), and assessed for fluorescence using a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
For each analysis, 4000 cells were evaluated and data were obtained
using CellQuest software.
Calcium flux studies
NRK52E cells were loaded with 2 mM Indo-1AM (Molecular Probes,
Eugene, OR, USA). Cells were then washed twice with Dulbecco’s
modified Eagle’s medium containing 1% fetal bovine serum and
resuspended at 5 106 cells ml1. Changes in intracellular calcium
were monitored by flow cytometry (BD LSR II; BD Biosciences)
after stimulation with nicotine (106 M) with or without 15 min
prior incubation with the cholinergic antagonist, hexamethonium
(103 M). Data analysis was performed with FlowJo software.
Reverse transcription-PCR
RNA was extracted from NRK52E cells using RNeasy mini kit
(Qiagen, Valencia, CA, USA), following the manufacturer’s protocol.
cDNA synthesis and PCR were performed in a single tube using
gene-specific primers and total RNA by SuperScript One-Step
reverse transcription-PCR with a Platinum Taq kit (Invitrogen,
Carlsbad, CA, USA) using a GeneAmp PCR system 9600 (Perkin-
Elmer Life and Analytical Sciences, Waltham, MA, USA) as follows:
1 cycle at 50 1C for 30 min, 1 cycle at 94 1C for 3 min, 35 cycles
at 94 1C for 30 s, 55–57 1C for 1 min, for individual transcripts
(see Table 1), 72 1C for 1 min, with a final extension step at 72 1C for
7 min. Primer sequences were selected from the unique cytoplasmic
domain region of each nAChR subunit and are essentially those used
by Liu et al.47 Glyceraldehyde-3-phosphate dehydrogenase was used
as an internal control to verify the efficiency of RNA isolation and
cDNA synthesis. PCR products were run on a 1.5% agarose gel
containing ethidium bromide and visualized under ultraviolet
illumination.
Bilateral subdiaphragmatic vagotomy
Rats were anesthetized with ketamine (100 mg kg1) and xylazine
(10 mg kg1) given intramuscularly. Access to the abdominal cavity
was gained through a midline abdominal incision. By applying
traction on the stomach with a cotton applicator, the esophagus was
brought into view without manipulation of the liver. At the
gastroesophageal junction, the two vagal trunks were identified on
either side of the esophagus, and were carefully separated and ligated
with the help of forceps. The incision was closed with 4-0 sutures.
Postoperatively, the animals were monitored daily for 2 days before
induction of renal I/R injury.
Renal ischemia model
An established model of renal I/R injury in rats was used.16,35,36 In
brief, male Sprague–Dawley rats were anesthetized by intraperitoneal
injection of ketamine (100 mg kg1) and xylazine (10 mg kg1).
A midline abdominal incision was made to expose the kidneys.
Blood supply to the kidneys was interrupted by the application of
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non-traumatic microvascular clamps (Fine Science Tools, Foster
City, CA, USA) around both renal arteries. Ischemia was confirmed
by blanching of the kidneys. After 45 min, the clamps were removed
and reperfusion was confirmed visually. The wound was then closed
in two layers with a 4-0 silk suture and the animals were allowed to
recover with free access to food and water. During the experiment,
the animals were kept hydrated with normal saline instilled
intraperitoneally and were kept on warm heating pads to maintain
body temperature. Sham operations were performed in a similar
way, except for clamping of the renal arteries. All the animals were
euthanized by carbon dioxide inhalation at 24 h post-reperfusion.
Blood was immediately collected in heparinized syringes via cardiac
puncture and the kidneys were rapidly excised.
Determination of plasma creatinine
Heparinized blood was centrifuged at 1000 g for 10 min at 4 1C
to separate the plasma, which was subsequently removed and stored
at 80 1C until creatinine measurement. Plasma creatinine (mg per
100 ml) was measured on a Roche Modular automated system
(Roche, Nutley, NJ, USA) by the Core Laboratory of the North
Shore—LIJ Health System.
MPO assay
Portions of kidneys were frozen immediately after removal and
stored at 80 1C until measurement of MPO activity. Tissue samples
were homogenized in 5% (wt/vol) 0.05 M potassium phosphate
buffer (pH 6.0) containing 0.5% hexadecyltrimethylammonium
bromide and sonicated for 30 s. After two freeze and thaw cycles,
with sonication between cycles, the samples were centrifuged at
11 000 g for 15 min at 4 1C and the supernatant was collected. A 7 ml
portion of aliquots of supernatant was added to 203 ml of reaction
mixture containing 0.05 M potassium phosphate buffer (pH 6.0),
0.167 mg ml1 o-dianisidine, and 0.05% H2O2. Change in absor-
bance over 4 min was measured at 450 nm using a spectro-
photometer. One unit of enzyme activity was defined as change in
absorbance (abs) of 1 per min. The MPO results are expressed as abs
per min per g of wet tissue.
Determination of renal levels of TNF
Kidney samples were homogenized in phosphate-buffered saline
containing a protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN, USA). The homogenate was first centrifuged at
2000 g for 10 min at 4 1C, and the supernatant was removed and
centrifuged at 10 000 g for 10 min at 4 1C. The supernatant was
stored at 80 1C until measurement of TNF-a. Renal levels of
TNF-a were measured using a rat TNF-a sandwich enzyme-linked
immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA),
according to the manufacturer’s instructions. All samples were tested
in duplicate. Results were expressed as TNF (ng) per mg protein
(determined by the Bio-Rad protein assay; Bio-Rad, Hercules, CA,
USA).
Histopathological studies of the kidneys
Formalin (10%)-fixed kidney samples were embedded in paraffin.
Sections (4mm) were prepared and stained with hematoxylin and
eosin. The slides were reviewed and scored using a semiquantitative
scale designed to assess the degree of tubular necrosis by a
pathologist unaware of the experimental groups, as previously
described.36 The scoring ranged between 0 and 4; it is based on the
percentage of tubules affected (0: o10%; 1: 10–25%; 2: 25–50%; 3:
50–75%; 4: 475%). Neutrophil infiltration into the interstitium was
quantified by a naphthol-AS-D-chloroacetate esterase staining
method (Leder staining). Ten high-power fields (magnification
 400) of each variable were reviewed in each slide and the mean
was recorded.
Table 1 | Primer sequences
Sequence
Annealing
temperature
Product
size
a1
50-TGGAAGCACTGGGTGTTTTA-30 53 288
50-AACATGTACTTCCCGATCAGG-30
a2
50-TGCCCAGGTGGCTGATGATGAACC-30 57 300
50-GCTTTCTGTATTTGAGGTGACAGC-30
a3
50-AACCTGCTCCCCAGGGTCATGTTT-30 55 300
50-CACTTTGGATGGCTTCTTTGATTT-30
a4
50-GTCAAAGACAACTGCCGGAGACTT-30 57 300
50-TGATGAGCATTGGAGCCCCACTGC-30
a5
50-GTGGATTTAGTGAGCAGTCATGCA-30 55 300
50-TTTGGGGGGAGTTTTAAATAGTCT-30
a6
50-CAGGTCTTCCCCTCGATTCTGATG-30 57 300
50-CATTGTGGCTTTTCATGTTTTCTG-30
a7
50-AACTGGTGTGCATGGTTTCTGCGC-30 57 300
50-AGATCTTGGCCAGGTCGGGGTCCC-30
a9
50-ATCCTGAAGTACATGTCCAGGATC-30 57 300
50-TGGCCTTGTGGTCCTTGAGGCACT-30
a10
50-TAGCCAGTCTCTCCCCAAA-30 57 209
50-GCTGGAATTACCGTGCTCA-30
b1
50-ATAGCTCAGTAAGGCCGGCG-30 57 355
50-TAGGTGACCTGGATGCTGCA-30
b2
50-ACGGTGTTCCTGCTGCTCATC-30 57 507
50-CACACTCTGGTCATCATCCTC-30
b3
50-GAAGATGTGGATACATCGTTTCCA-30 57 300
50-GAGCAGAGGGAGTAGTTCAGGAAC-30
b4
50-ATGAAGCGTCCCGGTCTTGAAGTC-30 57 300
50-GGTCATCGCTCTCCAGATGCTGGG-30
d
50-CAGCCGTCTACAGTGGGATG-30 55 235
50-CTGCCAGTCGAAAGGGAAGTA-30 291
g
50-GATGCAATGGTGCGACTATCGC-30 55 360
50-GCCTCCGGGTCAATGAAGATCC-30 244
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Statistical analysis
All data are expressed as means±s.e.m. Multiple-group compa-
risons were performed using analysis of variance followed by
Bonferroni post hoc testing and Student’s t-test for experiments with
only two subgroups. Statistical significance was set at Po0.05.
Correlation testing was performed between plasma creatinine levels
and tubular necrosis scores using Pearson’s correlation coefficient
testing.
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